Compare IDEXX Laboratories, Inc. (IDXX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nomura Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Nomura Holdings Inc trades at $9.61 (market cap $27.55B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.4% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Nomura Holdings Inc for 55 Days on average.
| IDXX | NMR | |
|---|---|---|
Market Cap | $40.43B | $27.55B |
Volume | 692,164 | 782,470 |
Sector | Health | Financials |
52-Week High | $766.68 | $10.86 |
52-Week Low | $504.70 | $6.73 |
Typical Hold Time | 46 Days | 55 Days |
Enterprise Value | $41.32B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Nomura Holdings (NMR) trades at $9.59, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.66T to $1.98T projected for 2026, net income margin of 20.4%, and attractive valuation ratios including P/E of 11.33. Recent news highlights technical pattern recognition and inclusion on Zacks Strong Buy lists, though cash flow trends show operational challenges.
NMR presents a mixed outlook with undervalued fundamentals against bearish technicals. Investment opportunity lies in discounted valuation and earnings momentum, but risks include negative operating cash flows, rising debt-to-asset ratios, and inconsistent earnings performance. Analyst consensus leans cautious with 67% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
